Pfizer and Valneva report Phase 3 trial results for Lyme disease vaccine candidate PF-07307405
Here's what it means for you.
The development of a Lyme disease vaccine could impact public health initiatives and travel safety, particularly for professionals frequently traveling to endemic areas.
What happened
On March 23, 2026, Pfizer and Valneva released topline results from their Phase 3 VALOR trial, showing a 73.2% efficacy of their Lyme disease vaccine candidate PF-07307405.
The Context
- Lyme disease prevalence: Approximately 476,000 cases occur annually in the U.S., highlighting a significant public health concern.
- Vaccine history: The last approved Lyme vaccine was withdrawn in 2002 due to safety concerns, leaving a gap in preventative options.
- Regulatory plans: Despite missing the primary efficacy criterion, Pfizer and Valneva are moving forward with regulatory submissions, targeting a U.S. launch in late 2027.
The Number
— This represents the vaccine's efficacy in reducing confirmed Lyme disease cases, a significant finding that could influence vaccine acceptance and public health strategies.
Takeaway
As regulatory submissions progress, the focus will shift to how this vaccine can reshape Lyme disease prevention strategies in endemic regions.
Coverage of national news and events from across the United States.
"HuffPost is known for its progressive editorial stance, offering opinionated yet comprehensive coverage on social, political, and cultural topics."
— A47 Editor
Pfizer Lyme Disease Vaccine Shows 70% Efficacy, But Misses Statistical Goal
Pfizer's Lyme disease vaccine candidate has demonstrated a 70% efficacy rate in reducing infections during a phase 3 clinical trial, although it did not meet a critical statistical goal necessary for broader approval.
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren’t conclusive
Pfizer and Valneva have reported positive results from a clinical trial of an experimental Lyme disease vaccine, which has shown effectiveness in preventing the tick-borne illness. However, the findings are not yet conclusive, and the companies are s...
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
Pharmaceutical companies Pfizer and Valneva have announced positive topline results from their phase three study of a vaccine candidate aimed at combating Lyme disease. This development marks a significant step forward in the fight against this tick-...